ABSTRACT
To study the effect of nanomedicine on lower extremity deep vein thrombosis (LEDVT) and its correlation with susceptibility genes (SGs), preliminary nanoparticle LSA was constructed using lauric acid and stearic acid, and CTAB-HAuCL4-TEOS (CHT) was obtained using cetyltrimethyl ammonium bromide (CTAB), chloroauric acid (HAuCL4), and tetraethoxysilane (TEOS) to prepare UK-LSA-CHT by combining with urokinase (UK). Twenty rabbits were grouped into UK-LSA-CHT, LSA, UK, and D0 groups. Human umbilical vein endothelial cells (HUVEC) were selected for the cytotoxicity test. The plasma endothelin (ET-1), interleukin 6 (IL-6), and nuclear factor κβ (NF-κβ) of the rabbits were detected with the double antibody sandwich method. Expression of platelet activating factor (PAF) was detected by immunohistochemical staining. Genotype distribution was detected with the second-generation sequencing technology (SGST). The results showed that expressions of ET-1, IL-6, and NF-κβ) in the UK-LSA-CHT group were lower than those in the LSA group and the UK group after 12 hours (P < 0.05). Frequencies of allele G and T, and GT and TT genotype ratios of SG NOS3 rs1799983 in the UK -LSA-CHT group were less than those in LSA and UK groups (P < 0.05). The UK-LSA-CHT group had an observably lower value in PAF positive expression than LSA and UK groups (P < 0.05). In short, UK-LSA-CHT had a good biocompatibility and safety and a good therapeutic effect on LEDVT. N0S3 rs1799983 alleles G and T may be the key risk factors for the occurrence and development of LEDVT.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Data availability statement
All data, models, and code generated or used during the study appear in the submission.